Mayne Pharma (MYX AU): This Is A Buy
On the 21st Feb 2025, Mayne Pharma (MYX AU), a leader in dermatology and women’s health, entered into a Scheme Implementation Deed with US-based pharmaceutical outfit, Cosette Pharmaceuticals.
Cosette is offering A$7.40/share, a 37% premium to last close. The Offer has the backing of Mayne's two largest shareholder, Viburnum and Bruce Mathieson, collectively holding 14.1%.
Mayne has now revised the Scheme timeline, with completion targeted late June, early July. This is done.
Keep reading with a 7-day free trial
Subscribe to Aussie/Kiwi M&A/Events to keep reading this post and get 7 days of free access to the full post archives.